新型长效核苷(酸)类似物治疗慢性乙型肝炎的应用前景

摘要/Abstract

摘要： 核苷(酸)类似物(NAs)治疗CHB患者可有效抑制HBV复制,口服方便且耐受性好。但目前即使一线的NAs也很难获得临床治愈,治疗疗程长、停药后复发率高。以追求临床治愈为目标的新靶点创新药物和新型长效NAs一直是抗HBV治疗药物研发的热点。本文主要通过阐述目前一线NAs治疗CHB存在的问题和新型长效NAs治疗CHB的优势,探讨新型长效NAs治疗CHB的应用前景。

魏舒琦, 丁洋. 新型长效核苷(酸)类似物治疗慢性乙型肝炎的应用前景[J]. 肝脏, 2021, 26(12): 1313-1315.

[1] 中华医学会感染病学分会,中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版). 中华肝脏病杂志, 2019, 27: 938-961.
[2] Liem KS, Fung S, Wong DK, et al. Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study). Gut, 2019, 68:2206-2213.
[3] Kao JH, Berg T. Nucleos(t)ide analogues in patients with chronic hepatitis B: to stop or not to stop? Gut, 2019, 68:2105-2106.
[4] Kuo MT, Hu TH, Hung CH, et al. Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir. Aliment Pharmacol Ther, 2019, 49:218-228.
[5] Fanning GC, Zoulim F, Hou J, et al. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov, 2019, 18:827-844.
[6] Buti M, Riveiro-Barciela M, Esteban R. Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B. Liver Int, 2018, 38:84-89.
[7] Kim JH, Sinn DH, KangW, et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. Hepatology, 2017, 66: 335-343.
[8] Shin JW, Jung SW, Lee SB, et al. Medication nonadherence increases hepatocellular carcinoma, cirrhotic complications, and mortality in chronic hepatitis B patients treated with entecavir. Am J Gastroenterol, 2018, 113: 998-1008.
[9] Ford N, Scourse R, Lemoine M, et al. Adherence to nucleos(t)ide analogue therapies for chronic hepatitis B infection: a systematic review and meta-analysis. Hepatol Commun, 2018, 2:1160-1167.
[10] Tao YC, Wang ML, Zhang DM, et al. Optimal drug administration manner would rescue partial virological response in chronic hepatitis B patients with entecavir or tenofovir treatment. J Viral Hepat, 2020, 27:731-738.
[11] Agarwal K, Brunetto M, Seto WK, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol, 2018, 68:672-681.
[12] Kim GA, Lim YS, An J, et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut, 2014, 63:1325-1332.
[13] Jeng WJ, Chen YC, Chien RN, et al. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen negative chronic hepatitis B. Hepatology, 2018, 68:425-434.
[14] Chen CH, Hung CH, Hu TH, et al. Association between level of hepatitis B surface antigen and relapse after entecavir therapy for chronic hepatitis B virus infection. Clin Gastroenterol Hepatol, 2015, 13:1984-1992.e1.
[15] Chen CH, Hung CH, Wang JH, et al. Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients. Clin Microbiol Infect, 2018, 24:997-1003.
[16] Seto WK, Liu KS, Mak LY, et al. Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation. Gut, 2021, 70:775-783.
[17] Fan R, Peng J, Xie Q, et al. Combining hepatitis B virus RNA and hepatitis B core-related antigen: guidance for safely stopping nucleos(t)ide analogues in hepatitis B e antigen-positive patients with chronic hepatitis B. J Infect Dis, 2020, 222:611-618.
[18] Kao JH, Jeng WJ, Ning Q, et al. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients.Hepatol Int, 2021, 15:833-851.
[19] Liaw YF. Hepatitis B fare after cessation of nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B: to retreat or not to retreat. Hepatology, 2021, 73(2): 843-852.
[20] Jeng WJ, Chang ML, Liaw YF. Off-therapy precipitous HBsAg decline predicts HBsAg loss after finite entecavir therapy in HBeAg-negative patients. J Viral Hepat, 2019, 26:1019-1026.
[21] 张鹭,江建宁. HBeAg阴性慢性乙型肝炎患者停用核苷(酸)类似物后复发的机制及再治疗策略进展. 肝脏, 2021, 26:477-479.
[22] Durantel D, Dousson CB, Lampertico P. Is there any need for new, long-acting nucleos(t)ide analogues for the treatment of hepatitis B infection? J Hepatol, 2021, 74:1011-1014.
[23] Higashi-Kuwata N, Hayashi S, Kumamoto H, et al. Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV. J Hepatol, 2021, 74:1075-1086.
[24] Lai CL, Wong D, Ip P, et al. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. J Hepatol, 2017, 66:275-281.

新型长效核苷(酸)类似物治疗慢性乙型肝炎的应用前景

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	肖倩倩, 王梦雨, 范建高. 非酒精性脂肪性肝病综合诊疗模式[J]. 肝脏, 2021, 26(9): 951-952.
[2]	孟方园, 孙悦, 苑广菲, 高沿航. 噬菌体在酒精性肝病治疗中的应用进展[J]. 肝脏, 2021, 26(9): 956-957.
[3]	许梓萌, 李德瑶, 席婧媛, 鲁凤民. 从HBV X蛋白的生物学功能看靶向HBx临床治愈慢性乙型肝炎的可能性[J]. 肝脏, 2021, 26(8): 832-834.
[4]	张思越, 甘建和. 慢加急性肝衰竭防治的研究进展[J]. 肝脏, 2021, 26(8): 928-931.
[5]	刘玉, 邹颖, 张正国, 郭红英, 梅雪, 王介非, 钱志平. 糖皮质激素成功救治急性肝衰竭1例[J]. 肝脏, 2021, 26(8): 945-946.
[6]	殷霖霖, 赵思, 张秀华, 季国忠. 混合型肝细胞-胆管癌的诊疗进展[J]. 肝脏, 2021, 26(7): 720-723.
[7]	黄晓铨, 吴玲, 姜思雨, 李锋, 陈世耀. 丙型肝炎持续病毒应答与肝硬化食管胃静脉曲张患者内镜治疗后再出血的相关性[J]. 肝脏, 2021, 26(6): 597-601.
[8]	段兴刚, 刘立, 刘良婷, 王应甜, 范群雄. 慢性乙型肝炎患者停药导致肝衰竭发生的特征及影响预后的相关因素分析[J]. 肝脏, 2021, 26(6): 617-620.
[9]	梁书菀. 肝癌合并门静脉癌栓微创治疗的进展分析[J]. 肝脏, 2021, 26(6): 703-705.
[10]	吉晓妹, 邵春燕, 吉浩明, 顾春燕. 人血白蛋白序贯治疗对原发性肝癌合并肝硬化患者射频消融术后肝功能和预后的影响[J]. 肝脏, 2021, 26(5): 534-537.
[11]	董晓锋, 杨英豪, 张燕, 王建斌, 朱晓红, 刘妲妲, 梁栋. 原发性肝癌治疗现状及MDT治疗模式的探讨[J]. 肝脏, 2021, 26(3): 262-265.
[12]	刘理冠, 叶巧霞, 严彦, 颜燕燕, 黄志杰, 张小曼. 慢性HBV相关肝病患者HBV基因型和耐药突变位点与疾病进展的关系[J]. 肝脏, 2021, 26(3): 287-290.
[13]	史冬梅, 刘芸野, 王伟静, 项晓刚. 成人慢性活动性EB病毒感染的临床特点及预后分析[J]. 肝脏, 2021, 26(2): 182-186.
[14]	杨菁, 范建高. PPARα/γ双重激动剂治疗非酒精性脂肪性肝病[J]. 肝脏, 2021, 26(12): 1311-1312.
[15]	庄华庆, 蒋华, 杨怡静. 旋转数字减影血管造影三维重建在肝癌介入治疗中的应用研究[J]. 肝脏, 2021, 26(12): 1328-1331.